Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM3HIQY)

• Drug Name: Melanoma vaccine (ALVAC) Drug Info
• Synonyms: Melanoma vaccine (ALVAC), sanofi pasteur; Melanoma vaccine (gp100/MAGE-1/MAGE-3/MART-1/NY-ESO-1, ALVAC), sanofi pasteur

Indication

Disease Entry	ICD 11	Status	REF
Melanoma	2C30	Discontinued in Phase 2	[1]

• Cross-matching ID: TTD Drug ID: DM3HIQY

Molecule-Related Drug Atlas

Drug(s) Targeting Melanoma-associated antigen 1 (MAGEA1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
CAR-T cells targeting MAGE-A1	DM1W7LV	Lung cancer	2C25.0	Phase 1/2	[3]

Drug(s) Targeting Melanocytes lineage-specific antigen GP100 (PMEL)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tebentafusp	DMUJ1WV	Gastric cancer	2B72	Approved	[4]
Multi-epitope peptide melanoma vaccine	DMZPEHY	Melanoma	2C30	Phase 3	[5]
Melanoma vaccine	DMQEC6Z	Melanoma	2C30	Phase 3	[6]
Multi-epitope tyrosinase/gp100 vaccine	DMN68ZL	Melanoma	2C30	Phase 2	[7]
Gp100:209-217(210M) peptide vaccine	DM38ARE	Melanoma	2C30	Phase 2	[8]
AE-08	DM7X2HK	Melanoma	2C30	Phase 1	[9]

Drug(s) Targeting Melanoma-associated antigen 3 (MAGEA3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Astuprotimut-R	DMLY0H5	Non-small-cell lung cancer	2C25.Y	Phase 3	[10]
Polynoma-1	DM3QDA6	Melanoma	2C30	Phase 2	[11]
IDM-2101	DMABRXY	Colorectal cancer	2B91.Z	Phase 2	[12]
GL-0817	DM17OZM	Head and neck cancer	2D42	Phase 2	[13]
KITE-718	DMBSI6Y	Solid tumour/cancer	2A00-2F9Z	Phase 1	[14]

Drug(s) Targeting MART-1 melanoma antigen (MLANA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Multi-epitope peptide melanoma vaccine	DMZPEHY	Melanoma	2C30	Phase 3	[5]
Melanoma vaccine	DMQEC6Z	Melanoma	2C30	Phase 3	[6]
Polynoma-1	DM3QDA6	Melanoma	2C30	Phase 2	[11]
MKC-1106-MT	DMXKOW6	Melanoma	2C30	Phase 2	[15]
F-50040	DMMG6W5	Melanoma	2C30	Discontinued in Phase 1	[16]

Drug(s) Targeting Cancer/testis antigen 1 (NY-ESO-1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
CDX-1401	DMCGNJ6	Ovarian cancer	2C73	Phase 2	[17]
CV-9201	DMCPZYT	Non-small-cell lung cancer	2C25.Y	Phase 1/2	[18]
Anti-NY-ESO-1 CAR-T cells	DM26VCZ	Esophageal cancer	2B70	Phase 1/2	[19]
NY-ESO-1 vaccine	DM0EKUQ	Solid tumour/cancer	2A00-2F9Z	Phase 1	[20]
GSK-2241658A	DM5VS7B	Melanoma	2C30	Phase 1	[21]
GSK3901961	DMN4I7P	Solid tumour/cancer	2A00-2F9Z	Phase 1	[22]
GSK3845097	DM1UQ4Y	Solid tumour/cancer	2A00-2F9Z	Phase 1	[22]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Cancer/testis antigen 1 (NY-ESO-1)	TTE5ITK	CTG1B_HUMAN	Not Available	[2]
MART-1 melanoma antigen (MLANA)	TT362RB	MAR1_HUMAN	Not Available	[2]
Melanocytes lineage-specific antigen GP100 (PMEL)	TT8MK59	PMEL_HUMAN	Not Available	[2]
Melanoma-associated antigen 1 (MAGEA1)	TT63M7Q	MAGA1_HUMAN	Not Available	[2]
Melanoma-associated antigen 3 (MAGEA3)	TTWSKHD	MAGA3_HUMAN	Not Available	[2]

References

• [1] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014153)
• [2] Preclinical qualification of a new multi-antigen candidate vaccine for metastatic melanoma. J Immunother. 2010 Oct;33(8):743-58.
• [3] ClinicalTrials.gov (NCT03356808) Antigen-specific T Cells Against Lung Cancer
• [4] Bi-specific TCR-anti CD3 redirected T-cell targeting of NY-ESO-1- and LAGE-1-positive tumors
• [5] Safety and immunogenicity of vaccination with MART-1 (26-35, 27L), gp100 (209-217, 210M), and tyrosinase (368-376, 370D) in-adjuvant with PF-3512676 and GM-CSF in metastatic melanoma. Correction in: volume 35 on page 650.
• [6] National Cancer Institute Drug Dictionary (drug id 685201).
• [7] ClinicalTrials.gov (NCT00003362) Vaccine Therapy Plus Immune Adjuvants in Treating Patients With Advanced Melanoma. U.S. National Institutes of Health.
• [8] National Cancer Institute Drug Dictionary (drug id 476335).
• [9] Synthesis of labeled BCX-4208, a potent inhibitor of purine nucleoside phosphorylase. Drug Test Anal. 2009 Mar;1(3):125-7.
• [10] National Cancer Institute Drug Dictionary (drug id 600553).
• [11] An immuno-oncology company developing a novel polyvalent antigen therapy for the treatment of melanoma. Polynoma. 2015.
• [12] Induction of immune responses and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung cancer. J Clin Oncol. 2008 Sep 20;26(27):4418-25.
• [13] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [14] ClinicalTrials.gov (NCT03139370) Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Adults With Advanced Cancers. U.S. National Institutes of Health.
• [15] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [16] Stability and CTL-activity of P40/ELA melanoma vaccine candidate. Biologicals. 2001 Sep-Dec;29(3-4):293-8.
• [17] National Cancer Institute Drug Dictionary (drug id 651880).
• [18] National Cancer Institute Drug Dictionary (drug id 648549).
• [19] ClinicalTrials.gov (NCT03638206) Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
• [20] Multiepitope CD8+ T cell response to a NY-ESO-1 peptide vaccine results in imprecise tumor targeting. J Clin Invest. 2002 December 15; 110(12): 1813-1822.
• [21] ClinicalTrials.gov (NCT01213472) Evaluation of a New Anti-cancer Immunotherapy in Patients With Non-operable and Progressing Metastatic Cutaneous Melanoma. U.S. National Institutes of Health.
• [22] Clinical pipeline report, company report or official report of GlaxoSmithKline.